Clinical Trial Update: Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of HM15912 (Sonefpeglutide) in subjects with normal and severe kidney function has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• Sonefpeglutide (HM15912) (Sonefpeglutide)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2025-04-04